AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02582723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein/high fat creme cheese
Description: Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
Study NCT00568945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capadenoson (BAY68-4986)
Description: 4 mg BAY68-4986 for five days
Study NCT00326469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: 120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
Study NCT02727166 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
Study NCT02727166 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrine
Description: Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
Study NCT02624323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided central vein catheterization.
Study NCT03373487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The cognitive rehabilitation program ReMind
Description: Cognitive rehabilitation, i.e. psychoeducation, strategy training \& retraining
Study NCT03373487 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The cognitive rehabilitation program ReMind
Description: Cognitive rehabilitation, i.e. psychoeducation, strategy training \& retraining
Study NCT00577161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine and rituximab
Description: days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
Study NCT00577161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine, rituximab, pixantrone
Description: days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
Study NCT04922489 — intervention group
Intervention type: PROCEDURE
Intervention: Dental implant placement
Description: Dental implant placemente on edentulous jaw.
Study NCT01020448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin (Decapeptyl®)
Description: One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
Study NCT01938469 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Liquid Meal
Study NCT01938469 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Solid Meal
Study NCT04127149 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound scan
Description: The group uses an ultrasound device for the consultation.
Study NCT01207661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Injection
Description: Intra Articular Injection of Mesenchymal cells to the knee joint
Study NCT00514657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)
Study NCT00514657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)
Study NCT01566656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: total lymphoid irradiation and anti-thymocyte globulin
Description: * TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.~* ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.~* Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.~* GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0
Study NCT02866110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: The Blood Oxygenation Level Dependent (BOLD) signal from the amygdala, recorded with functional magnetic resonance imaging, is utilized as a feedback signal to patients.
Study NCT02866110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Echo-planar Imaging of brain BOLD signal
Study NCT02367365 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study NCT00508248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3 fatty acids
Description: 1g daily
Study NCT00508248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: olive oil capsule
Study NCT00984763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel® + CPG 7909
Description: A 0.55 mL dose of AMA1-C1/Alhydrogel® + CPG 7909 (corresponds to 80 µg of AMA1-C1 and 564 µg of CPG 7909)
Study NCT03708822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Cisplatin and Nimotuzumab
Description: Intravenous nimotuzumab (200 mg on days 1, 8, and 15) ; Intravenous docetaxel (75 mg/m2 on day 1) ; Intravenous cisplatin (75 mg/m2 on day 1) ;
Study NCT03379922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress balls
Description: Squeezing stress balls while receiving ESWL treatment
Study NCT03379922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headphones
Description: Listening to music while receiving ESWL treatment
Study NCT02975024 — intervention group
Intervention type: DEVICE
Intervention: laser speckle contrast imaging of the oral mucosa
Description: Non-invasive method to measure tissue blood perfusion applied for oral mucosa
Study NCT02975024 — intervention group
Intervention type: DEVICE
Intervention: wound fluid measurement
Description: Wound fluid at the wound margin is collected using filter strip and volumetrically measured by Periotron 8010 instrument.
Study NCT02975024 — intervention group
Intervention type: DEVICE
Intervention: quantitative determination of VEGF
Description: For the quantitative determination of VEGF in the fourth day wound fluid sample the Human VEGF Quantikine ELISA Kit will be used.
Study NCT05094466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive peer support sessions
Study NCT05094466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Receive health coaching sessions
Study NCT05094466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Attend focus groups
Study NCT05094466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Attend focus groups
Study NCT05094466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive handbook
Study NCT05094466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive handbook
Study NCT05094466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive navigation sessions
Study NCT05094466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview
Study NCT05094466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Participate in interview
Study NCT01764113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating
Description: Subjects and their parents will receive mindful eating based behavioral modification program over multiple sessions
Study NCT01764113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary counselling
Study NCT02645695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: routine pulmonary rehabilitation
Description: received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.
Study NCT02645695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chest wall vibration technique
Description: administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
Study NCT01349725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-502
Description: Oral; multiple dose, escalating
Study NCT01349725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral; matching placebo
Study NCT03739541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Benznidazole
Description: A single dose level of 100 mg; 200 μCi (7.4 MBq)
Study NCT00947713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose human chorionic gonadotropin
Description: patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate
Study NCT00947713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphen citrate plus HMG
Description: patients will receive Clomiphen Citrate plus HMG
Study NCT01474499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerine
Study NCT01474499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate sodium and sorbitol rectal solution
Study NCT02857998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: Oral administration, once daily
Study NCT01941134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol-levonorgestrel
Description: Women will be asked to take a daily ethinyl estradiol-levonorgestrel combined oral contraceptive (COC) for 21 days, beginning 2-3 months pre-operatively, so as to stop at least 30 days before planned surgery date. Then, approximately 3-4 months after surgery, they will again be asked to take a daily pill for 21 days. During these pill cycles, we will collect serum samples and perform ultrasound and cervical mucus assessments on a twice-weekly basis, culminating in an inpatient stay of up to 48 hours in order to obtain more frequent sampling at the end of the pill pack.
Study NCT03045042 — intervention group
Intervention type: DRUG
Intervention: Enzyme Replacement Agent
Description: Patients will be treated following the decision of their doctors. The investigators are going to analyze serum samples of these patients
Study NCT02521467 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelets Rich Fibrin in healing of palatal donor tissue
Description: Platelets Rich Fibrin (PRF) is a second generation of platelets concentrate full of growth factors as PDGF, IGF, TGF which had a role in hemostasis fasten the healing and decrease the pain.
Study NCT02521467 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the other group is a control group, had no biologic in the palatal wound, only palatal stent
Study NCT04729764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 Tablet
Description: Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.
Study NCT03985085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive package of sexual and reproductive health services
Description: Implementation of a comprehensive sexual and reproductive health care package for female sex workers in Côte d'Ivoire, combining an HIV PrEP offer (for HIV- FSW) with early treatment of HIV+ FSW, management of HBV infection (testing, vaccination and treatment), testing and treatment of sexually transmitted infections (STIs) and their consequences, a contraception offer, a quarterly screening of pregnancies, menstrual management counselling and identification of addiction.~This healthcare package will be available both in mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and in the fixed clinic of the partner community-based NGO, at the discretion of each female participant.
Study NCT04598204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with oral rapmycin
Description: To treat the enrolled patients with oral rapamycin with an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
Study NCT01198353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: 100% of the past antipsychotic dose will be maintained in week 1, using flexible dosing of 0-100% during next 3 weeks and then discontinued. Ziprasidone will be maintained with flexible dosing of 40-160mg/day during the study period.
Study NCT00388154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 900 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
Study NCT00388154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
Study NCT00544362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00544362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00544362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00544362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT03608540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina
Description: Suturing system with sutures apposition then bulging then cutting
Study NCT02918604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: infrared technology: Veinsite
Description: peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
Study NCT02918604 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: infrared technology: Veinsite
Description: peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
Study NCT00796120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.5 milligram per square meter (mg/m\^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
Study NCT00796120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 60 or 75 mg/m\^2 will be given intravenously every 3 weeks until disease progression.
Study NCT00796120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Ifosfamide 6 to 9 g/m\^2 will be given intravenously every 3 weeks until disease progression.
Study NCT01386281 — intervention group
Intervention type: DRUG
Intervention: E2 transdermal (Julina, BAY86-5435)
Description: Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
Study NCT00838929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: All doses given for 3 weeks~Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd
Study NCT00838929 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.
Study NCT00621387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofloxacin and roxithromycin
Description: 150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months
Study NCT00621387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets identical to ofloxacin and roxithromycin twice daily for 3 months
Study NCT00744185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol treatment
Description: 30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
Study NCT00744185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: 30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
Study NCT01121835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
Study NCT01121835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)
Study NCT01121835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PREMIXED INSULIN
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico~* 25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only
Study NCT02981654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alma Lasers Pixel carbon dioxide laser system
Description: The vaginal handpiece sheath is lubricated with baby oil. Set the initial energy level (startup set up recommendations: High mode, 40 millijoule/pixel; according to the patient reaction you can increase up to 120 max. Pulse mode or Repeat mode). The handpiece is inserted as distally as possible, with the laser energy's window oriented to the 12:00 o'clock position. There are position markings on the handpiece. Trigger a laser pulse by pressing the footswitch. Shoot the laser and rotate the probe by one hour at a time. When you reach the 12:00 o'clock position again, withdrawal the headpiece back by one centimeter and repeat the rotational treatment process.
Study NCT02092220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Study NCT02092220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump with or without CGM
Study NCT02605421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.
Study NCT02605421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
Study NCT02605421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan by IV once daily for 3 doses on Days -8, -7, and -6. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.
Study NCT02605421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.
Study NCT02605421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.
Study NCT02605421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Infusion
Description: On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
Study NCT02605421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor
Description: Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC > 2000/μL for 3 consecutive days.
Study NCT00461487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control on hygiene and nutrition
Description: The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.